Ascendis Pharma A S Adr (ASND)

On Monday, Ascendis Pharma disclosed that the FDA had identified inadequacies in its application for a gland treatment, leading to a significant decline in the value of the company's stock. The exact nature of the deficiencies remains unclear, and it is not yet known how this development will impact the timeline for regulatory approval or the overall prospects of the treatment.

https://www.investors.com/news/technology/asnd-stock-plunge-fda-delays-ascendis-drug-certification/

On Monday, Ascendis Pharma disclosed that the FDA had identified inadequacies in its application for a gland treatment, leading to a significant decline in the value of the company's stock. The exact nature of the deficiencies remains unclear, and it is not yet known how this development will impact the timeline for regulatory approval or the overall prospects of the treatment.

https://www.investors.com/news/technology/asnd-stock-plunge-fda-delays-ascendis-drug-certification/